If a person has a Medicare Part D prescription drug plan, it may cover the costs of Trelegy Ellipta inhalers. Although out-of-pocket costs can vary by plan ...
* TRELEGY ELLIPTA ONCE-DAILY SINGLE INHALER TRIPLE THERAPY RECEIVES POSITIVE OPINION FROM CHMP IN EUROPE FOR APPROPRIATE PATIENTS WITH COPD * TRELEGY ELLIPTA ONCE-DAILY SINGLE INHALER TRIPLE THERAPY ...
DUBLIN, June 2, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") today announced that it has entered into a definitive agreement to sell its remaining royalty ...
Theravance Biopharma TBPH announced that it has entered into an agreement to sell its remaining royalty interest in net sales of Trelegy Ellipta to GSK plc GSK for $225 million in cash. Theravance ...
The FDA approved United Kingdom-based GlaxoSmithKline’s Trelegy Ellipta, a once-daily inhaler that contains three medicines for chronic obstructive pulmonary disease. The inhaler, developed with the ...
* Theravance Biopharma highlights approval of trelegy ellipta (closed triple) as the first once-daily single inhaler triple therapy for the treatment of appropriate patients with COPD in the US Sign ...
After years of picking up royalties on GSK’s asthma and COPD inhaler Trelegy, Theravance Biopharma is opting to sell its remaining financial interest to GSK in exchange for a cash reward of $225 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results